The benign prostatic hyperplasia treatment market size has grown strongly in recent years. It will grow from $8.69 billion in 2025 to $9.17 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing aging male population, rising prevalence of urinary disorders, expansion of urology specialty services, growing use of pharmacological treatments, improved access to diagnostic screening.
The benign prostatic hyperplasia treatment market size is expected to see strong growth in the next few years. It will grow to $11.29 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing adoption of robotic-assisted prostate procedures, rising focus on personalized treatment planning, expansion of home-based therapy options, growing integration of digital patient monitoring tools, increasing demand for minimally invasive interventions. Major trends in the forecast period include increasing adoption of minimally invasive surgical techniques, rising demand for targeted drug therapies, growing use of combination treatment approaches, expansion of outpatient treatment settings, enhanced focus on symptom management and quality of life.
The increasing adoption of minimally invasive surgeries is anticipated to fuel future growth in the benign prostatic hyperplasia (BPH) treatment market. These procedures use small incisions or none at all, employing specialized tools to minimize recovery time, pain, and complication risks. Growing preference for minimally invasive surgeries stems from advantages like faster recovery, less pain, fewer complications, and better aesthetic results. BPH treatments via these minimally invasive methods offer patients quicker healing, reduced complication risks, and reliable symptom management, leading to superior surgical results overall. For instance, in September 2023, the American Society of Plastic Surgeons (ASPS), a U.S.-based professional organization, reported nearly 25.4 million minimally invasive cosmetic procedures in 2023, a 7% increase from 23.7 million in 2022. Thus, the surge in minimally invasive surgery adoption is boosting the benign prostatic hyperplasia treatment market.
Key players in the benign prostatic hyperplasia treatment market are prioritizing the creation of novel approaches, like intraprostatic drug elution therapy, to secure a market edge. This therapy entails inserting a bioabsorbable implant straight into the prostate for sustained local release of medication. For example, in May 2025, Resurge Therapeutics - a U.S.-based innovator in urology tech - launched a paclitaxel-releasing bioabsorbable implant for BPH, featuring easy office-based placement, precise drug delivery, and little discomfort afterward. Such targeted administration cuts down on body-wide side effects, boosts treatment effectiveness, and maintains sexual function. Still, its extended safety profile and widespread use are yet to be fully assessed.
In October 2023, Laborie Medical Technologies, Inc., a US-based medical technology firm, purchased Urotronic for $600 million. Through this acquisition, Laborie Medical Technologies seeks to broaden its interventional urology offerings, advance its technological expertise, and bolster its worldwide standing in minimally invasive urological therapies. Urotronic, Inc. is a US-based medical device firm focused on developing and commercializing a minimally invasive therapy for benign prostatic hyperplasia (BPH).
Major companies operating in the benign prostatic hyperplasia treatment market are Astellas Pharma Inc., Bayer AG, Pfizer Inc., Merck & Co Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi S.A., Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, Cook Medical Incorporated, Coloplast Group, Medtronic Public Limited Company, Urovant Sciences Ltd., UroGen Pharma Ltd., Urologix Inc., Zenflow Inc., HistoSonics Inc.
North America was the largest region in the benign prostatic hyperplasia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the benign prostatic hyperplasia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the benign prostatic hyperplasia treatment market by increasing costs of imported surgical instruments, robotic systems, diagnostic equipment, and pharmaceutical ingredients used in both medical and surgical treatment pathways. Hospitals and clinics in North America and Europe are most affected due to dependence on imported advanced urology equipment, while Asia-Pacific faces cost pressures on pharmaceutical manufacturing. These tariffs are raising treatment costs and slowing technology adoption. However, they are also encouraging domestic production of medical devices, regional pharmaceutical manufacturing, and investment in locally developed minimally invasive treatment technologies.
The benign prostatic hyperplasia treatment market research report is one of a series of new reports that provides benign prostatic hyperplasia treatment market statistics, including benign prostatic hyperplasia treatment industry global market size, regional shares, competitors with a benign prostatic hyperplasia treatment market share, detailed benign prostatic hyperplasia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia treatment industry. This benign prostatic hyperplasia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Treatments for benign prostatic hyperplasia (BPH) include medical, minimally invasive, and surgical options to address symptoms of an enlarged prostate. BPH affects many older men, causing urinary problems like frequent urination, weak urine flow, and incomplete bladder emptying.
The primary treatments for benign prostatic hyperplasia (BPH) consist of minimally invasive surgery (MIS) and invasive surgery. Minimally invasive surgery (MIS) involves surgical methods that employ small incisions, specialized tools, and advanced imaging to conduct procedures while causing minimal damage to the body. The drug categories for BPH management encompass alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and additional categories. These options serve diverse end users, such as home healthcare, hospitals and clinics, plus research and manufacturing sites.
The benign prostatic hyperplasia treatment market consists of revenues earned by entities by providing services such as pharmacological treatments, minimally invasive procedures, surgical treatments, diagnostic services, and prostatic stents. The market value includes the value of related goods sold by the service provider or included within the service offering. The benign prostatic hyperplasia treatment market also includes sales of transurethral microwave thermotherapy, prostatic urethral lift, acupuncture, combination therapy, phosphodiesterase-5 inhibitors, and minimally invasive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The benign prostatic hyperplasia treatment market size is expected to see strong growth in the next few years. It will grow to $11.29 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing adoption of robotic-assisted prostate procedures, rising focus on personalized treatment planning, expansion of home-based therapy options, growing integration of digital patient monitoring tools, increasing demand for minimally invasive interventions. Major trends in the forecast period include increasing adoption of minimally invasive surgical techniques, rising demand for targeted drug therapies, growing use of combination treatment approaches, expansion of outpatient treatment settings, enhanced focus on symptom management and quality of life.
The increasing adoption of minimally invasive surgeries is anticipated to fuel future growth in the benign prostatic hyperplasia (BPH) treatment market. These procedures use small incisions or none at all, employing specialized tools to minimize recovery time, pain, and complication risks. Growing preference for minimally invasive surgeries stems from advantages like faster recovery, less pain, fewer complications, and better aesthetic results. BPH treatments via these minimally invasive methods offer patients quicker healing, reduced complication risks, and reliable symptom management, leading to superior surgical results overall. For instance, in September 2023, the American Society of Plastic Surgeons (ASPS), a U.S.-based professional organization, reported nearly 25.4 million minimally invasive cosmetic procedures in 2023, a 7% increase from 23.7 million in 2022. Thus, the surge in minimally invasive surgery adoption is boosting the benign prostatic hyperplasia treatment market.
Key players in the benign prostatic hyperplasia treatment market are prioritizing the creation of novel approaches, like intraprostatic drug elution therapy, to secure a market edge. This therapy entails inserting a bioabsorbable implant straight into the prostate for sustained local release of medication. For example, in May 2025, Resurge Therapeutics - a U.S.-based innovator in urology tech - launched a paclitaxel-releasing bioabsorbable implant for BPH, featuring easy office-based placement, precise drug delivery, and little discomfort afterward. Such targeted administration cuts down on body-wide side effects, boosts treatment effectiveness, and maintains sexual function. Still, its extended safety profile and widespread use are yet to be fully assessed.
In October 2023, Laborie Medical Technologies, Inc., a US-based medical technology firm, purchased Urotronic for $600 million. Through this acquisition, Laborie Medical Technologies seeks to broaden its interventional urology offerings, advance its technological expertise, and bolster its worldwide standing in minimally invasive urological therapies. Urotronic, Inc. is a US-based medical device firm focused on developing and commercializing a minimally invasive therapy for benign prostatic hyperplasia (BPH).
Major companies operating in the benign prostatic hyperplasia treatment market are Astellas Pharma Inc., Bayer AG, Pfizer Inc., Merck & Co Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi S.A., Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, Cook Medical Incorporated, Coloplast Group, Medtronic Public Limited Company, Urovant Sciences Ltd., UroGen Pharma Ltd., Urologix Inc., Zenflow Inc., HistoSonics Inc.
North America was the largest region in the benign prostatic hyperplasia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the benign prostatic hyperplasia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the benign prostatic hyperplasia treatment market by increasing costs of imported surgical instruments, robotic systems, diagnostic equipment, and pharmaceutical ingredients used in both medical and surgical treatment pathways. Hospitals and clinics in North America and Europe are most affected due to dependence on imported advanced urology equipment, while Asia-Pacific faces cost pressures on pharmaceutical manufacturing. These tariffs are raising treatment costs and slowing technology adoption. However, they are also encouraging domestic production of medical devices, regional pharmaceutical manufacturing, and investment in locally developed minimally invasive treatment technologies.
The benign prostatic hyperplasia treatment market research report is one of a series of new reports that provides benign prostatic hyperplasia treatment market statistics, including benign prostatic hyperplasia treatment industry global market size, regional shares, competitors with a benign prostatic hyperplasia treatment market share, detailed benign prostatic hyperplasia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia treatment industry. This benign prostatic hyperplasia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Treatments for benign prostatic hyperplasia (BPH) include medical, minimally invasive, and surgical options to address symptoms of an enlarged prostate. BPH affects many older men, causing urinary problems like frequent urination, weak urine flow, and incomplete bladder emptying.
The primary treatments for benign prostatic hyperplasia (BPH) consist of minimally invasive surgery (MIS) and invasive surgery. Minimally invasive surgery (MIS) involves surgical methods that employ small incisions, specialized tools, and advanced imaging to conduct procedures while causing minimal damage to the body. The drug categories for BPH management encompass alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and additional categories. These options serve diverse end users, such as home healthcare, hospitals and clinics, plus research and manufacturing sites.
The benign prostatic hyperplasia treatment market consists of revenues earned by entities by providing services such as pharmacological treatments, minimally invasive procedures, surgical treatments, diagnostic services, and prostatic stents. The market value includes the value of related goods sold by the service provider or included within the service offering. The benign prostatic hyperplasia treatment market also includes sales of transurethral microwave thermotherapy, prostatic urethral lift, acupuncture, combination therapy, phosphodiesterase-5 inhibitors, and minimally invasive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Benign Prostatic Hyperplasia Treatment Market Characteristics
3. Benign Prostatic Hyperplasia Treatment Market Supply Chain Analysis
4. Global Benign Prostatic Hyperplasia Treatment Market Trends and Strategies
5. Benign Prostatic Hyperplasia Treatment Market Analysis of End Use Industries
7. Global Benign Prostatic Hyperplasia Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Benign Prostatic Hyperplasia Treatment Total Addressable Market (TAM) Analysis for the Market
9. Benign Prostatic Hyperplasia Treatment Market Segmentation
10. Benign Prostatic Hyperplasia Treatment Market Regional and Country Analysis
11. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market
12. China Benign Prostatic Hyperplasia Treatment Market
13. India Benign Prostatic Hyperplasia Treatment Market
14. Japan Benign Prostatic Hyperplasia Treatment Market
15. Australia Benign Prostatic Hyperplasia Treatment Market
16. Indonesia Benign Prostatic Hyperplasia Treatment Market
17. South Korea Benign Prostatic Hyperplasia Treatment Market
18. Taiwan Benign Prostatic Hyperplasia Treatment Market
19. South East Asia Benign Prostatic Hyperplasia Treatment Market
20. Western Europe Benign Prostatic Hyperplasia Treatment Market
21. UK Benign Prostatic Hyperplasia Treatment Market
22. Germany Benign Prostatic Hyperplasia Treatment Market
23. France Benign Prostatic Hyperplasia Treatment Market
24. Italy Benign Prostatic Hyperplasia Treatment Market
25. Spain Benign Prostatic Hyperplasia Treatment Market
26. Eastern Europe Benign Prostatic Hyperplasia Treatment Market
27. Russia Benign Prostatic Hyperplasia Treatment Market
28. North America Benign Prostatic Hyperplasia Treatment Market
29. USA Benign Prostatic Hyperplasia Treatment Market
30. Canada Benign Prostatic Hyperplasia Treatment Market
31. South America Benign Prostatic Hyperplasia Treatment Market
32. Brazil Benign Prostatic Hyperplasia Treatment Market
33. Middle East Benign Prostatic Hyperplasia Treatment Market
34. Africa Benign Prostatic Hyperplasia Treatment Market
36. Benign Prostatic Hyperplasia Treatment Market Competitive Landscape and Company Profiles
37. Benign Prostatic Hyperplasia Treatment Market Other Major and Innovative Companies
40. Benign Prostatic Hyperplasia Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Benign Prostatic Hyperplasia Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses benign prostatic hyperplasia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for benign prostatic hyperplasia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The benign prostatic hyperplasia treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment: Minimal Invasive Surgery; Invasive Surgery2) By Therapeutic Class: Alpha Blockers; 5-Alpha Reductase Inhibitors; Phosphodiesterase-5 Inhibitors; Other Therapeutic classes
3) By End User: Home Healthcare; Hospitals And Clinics
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP); Laser Surgery; Prostatic Urethral Lift; Transurethral Incision of the Prostate (TUIP); Microwave Therapy2) By Invasive Surgery: Open Prostatectomy; Robotic Prostatectomy
Companies Mentioned: Astellas Pharma Inc.; Bayer AG; Pfizer Inc.; Merck & Co Inc.; Eli Lilly and Company; AbbVie Inc.; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim; Sanofi S.A.; Boston Scientific Corporation; Olympus Corporation; Teleflex Incorporated; Cook Medical Incorporated; Coloplast Group; Medtronic Public Limited Company; Urovant Sciences Ltd.; UroGen Pharma Ltd.; Urologix Inc.; Zenflow Inc.; HistoSonics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Benign Prostatic Hyperplasia Treatment market report include:- Astellas Pharma Inc.
- Bayer AG
- Pfizer Inc.
- Merck & Co Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim
- Sanofi S.A.
- Boston Scientific Corporation
- Olympus Corporation
- Teleflex Incorporated
- Cook Medical Incorporated
- Coloplast Group
- Medtronic Public Limited Company
- Urovant Sciences Ltd.
- UroGen Pharma Ltd.
- Urologix Inc.
- Zenflow Inc.
- HistoSonics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 9.17 Billion |
| Forecasted Market Value ( USD | $ 11.29 Billion |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
